Qiagen N.V. (QGEN)

From the record

Qiagen N.V.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Qiagen N.V.'s 10 filed years say what it did: revenue went from $1.3 billion in fiscal 2016 to $2.1 billion in fiscal 2025, up 5.1% a year; it rose in 7 of 9 years; the deepest fall was 13% from fiscal 2021 to fiscal 2023; net income was positive in 9 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Qiagen N.V.'s diluted share count shrank about 1.7% a year, and dividends and buybacks returned about 35% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Qiagen N.V. earned about 11 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 21 cents per dollar of everything the company owns. Leverage: it owed about 40 cents per dollar of assets, and net share issuance: its share count shrank 2.6% over the year (the filed statements).

From the record

Qiagen N.V.'s standing among 102 graded names in its industry family: revenue of $2.1 billion in fiscal 2025 ranks in the top 5% by size; a net margin of 20.3% ranks in the top 14%; revenue growth of -0.8% a year over the last 3 filed years ranks in the bottom 39% (its annual reports).

From the record

Qiagen N.V.'s room to grow, from the newest filed statements (fiscal 2025): cash of $839 million against debt of $1.7 billion leaves -13% of its assets as net cash, bottom 5% of its family; cash from operations less capital spending is 21.7% of revenue (top 10%); a gross margin of 62.2% (bottom 41%); research spending of 9% of revenue (bottom 7%) (its annual report).

From the record

Qiagen N.V.'s growth drivers, from the filed years to fiscal 2025: revenue grew -0.8% a year over the last three filed years against 5.1% over all 10, slowing (top 49% of its family); the newest year grew 5.7% (bottom 43%); research spending grew -0.4% a year (bottom 48%); capital spending grew 15.9% a year (top 20%) (its annual reports). Qiagen N.V. reported 5 product lines in fiscal 2025: Diagnostic Solutions at $803 million (38%), Sample Technologies at $661 million (32%), PCR Nucleic Acid Amplification at $309 million (15%), and 2 more; 5 of 5 grew against the year before (its annual report).

From the record

Qiagen N.V.'s newest year against its own record: revenue of $2.1 billion in fiscal 2025 came in 9.9% above the $1.9 billion its prior three years' pace pointed to (top 42% of its family); net income of $425 million against a prior three-year average of $283 million (top 28%); a net margin of 20.3% against 13.8% before (bottom 41%) (its annual reports).